BHCM
BBNX icon

Brevan Howard Capital Management’s Beta Bionics BBNX Stock Holding History

Brevan Howard Capital Management’s Portfolio BBNX Stock Details BBNX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$527K Buy
+33,654
New +$400K ﹤0.01% 1422
2026
Q1 		– Sell
-9,607
Closed -$293K – 2576
2025
Q4 		$293K Buy
+9,607
New +$257K ﹤0.01% 1383

Other funds holding BBNX

EAM
Eventide Asset Management Boston, Massachusetts $7.48B AUM 104.76% 1-Year Est. Return
SCM
Soleus Capital Management Greenwich, Connecticut $2.9B AUM 169.69% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
SCV
Sands Capital Ventures Arlington, Virginia $614M AUM 19.92% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
VPC
Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
DM
Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return

Brevan Howard Capital Management's BBNX Position: Q2 2026 in Review

Brevan Howard Capital Management opened a new position in Beta Bionics (BBNX) in Q2 2026: 33,654 shares worth $527K. The stake represents ﹤0.01% of the portfolio and ranks #1422 among its holdings. This is a return to the name: Brevan Howard Capital Management previously reported a position in BBNX as recently as Q4 2025.

Brevan Howard Capital Management first reported a position in BBNX in Q4 2025 and has held it in 2 quarters since. 133 funds tracked by Wall St. Rank hold BBNX as of Q2 2026.

  • Brevan Howard Capital Management held 33,654 shares of Beta Bionics worth $527K as of Q2 2026.
  • Beta Bionics was a new Brevan Howard Capital Management position in Q2 2026.
  • Beta Bionics made up ﹤0.01% of Brevan Howard Capital Management's portfolio in Q2 2026, its #1422 holding.
  • Brevan Howard Capital Management first reported a position in Beta Bionics in Q4 2025 and has held it in 2 quarters since.
  • 133 funds tracked by Wall St. Rank held Beta Bionics as of Q2 2026.

Based on Brevan Howard Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.